Alveolar Bone Atrophy
Conditions
Keywords
Maxilla, mandible,, MSC, RCT, Bone regeneration, Multicenter
Brief summary
A randomized controlled clinical multi center trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in comparison to standard autologous bone block grafting.
Detailed description
A phase III multi center clinical trial, randomized and controlled.The study subject is lacking one or more sheet behind the canine in the upper or lower jaw, and the alveolar ridge is too narrow to place a dental implant. The test objects will have augmentation using autologous mesenchymal stromal cells and a biomaterial, biphasic Calcium Phosphate. The control is the traditional bone block from the ramus.
Interventions
COMBINATION_PRODUCTAdvanced medicinal Therapy (MSC combined with biomaterial)
Augmentation of alveolar ridge with MSC and biomaterial
PROCEDUREAutologous bone graft
Augmentation of the alveolar ridge with bone graft
Sponsors
Université de Nantes
University of Ulm
Universidad Complutense de Madrid
University of Aarhus
Universitat Internacional de Catalunya
Assistance Publique - Hôpitaux de Paris
European Commission
University of Bergen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomized controlled trial with advanced therapy medicinal product
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy, non smoking patients in need of dental implants in the upper or lower jaw, with loss in vertical height and less that 4 mm in lateral width.
Exclusion criteria
* General contraindications for dental and/or surgical treatments * Contraindications for both bone marrow harvesting and bone grafts * History of any malignant diseases * Concurrent or previous radiotherapy of head and neck region * History of contagious diseases (HIV, HTLV and/or syphilis seropositivity, hepatitis B or C infection) * Uncontrolled diabetes mellitis, e.g. patients with diabetes not regulated with medications or diet. This will be verified based on patient's history and concurrent HbA1c levels (HbA1c \> 53 mmol/mol). * Inflammatory and autoimmune disease of the oral cavity. * Concurrent or previous immunosuppressant, bisphosphonate or high dose corticosteroid therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in bone width | 0-5 months | Changes in linear measurements of bone width measured by CBCT.Principal assessment is linear change in bone width 2 mm below alveolar crest measured by means of CBCT images from baseline to 5 months after the regenerative surgery, immediately prior to implant placement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain postoperatively in the two different treatments | 21 months | Assessed by VAS scale, the scale goes from 0 to 100, 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of no pain at all and worst pain imaginable. |
| Radiological examination of bone volume | 21 months | To evaluate the formation of the new bone by assessing if it is possible to insert an implant in the reconstructed area 5 months after the grafting procedure. This decision will be made based on radiological examination of bone volume by means of 3D CBCT images captured immediately prior to implant placement, 5-6 months after the regenerative surgery. |
Countries
Denmark, France, Norway, Spain
Outcome results
None listed